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ABSTRACT
Introduction Diet, shown to impact colorectal cancer 
(CRC) risk, is a modifiable environmental factor. Fibre 
foods fermented by gut microbiota produce metabolites 
that not only provide food for the colonic epithelium 
but also exert regulatory effects on colonic mucosal 
inflammation and proliferation. We describe methods 
used in a double- blinded, randomised, controlled trial 
with Alaska Native (AN) people to determine if dietary 
fibre supplementation can substantially reduce CRC risk 
among people with the highest reported CRC incidence 
worldwide.
Methods and analyses Eligible patients undergoing 
routine screening colonoscopy consent to baseline 
assessments and specimen/data collection (blood, urine, 
stool, saliva, breath and colon mucosal biopsies) at the 
time of colonoscopy. Following an 8- week stabilisation 
period to re- establish normal gut microbiota post 
colonoscopy, study personnel randomise participants 
to either a high fibre supplement (resistant starch, 
n=30) or placebo (digestible starch, n=30) condition, 
repeating stool sample collection. During the 28- day 
supplement trial, each participant consumes their usual 
diet plus their supplement under direct observation. On 
day 29, participants undergo a flexible sigmoidoscopy 
to obtain mucosal biopsy samples to measure the effect 
of the supplement on inflammatory and proliferative 
biomarkers of cancer risk, with follow- up assessments 
and data/specimen collection similar to baseline. 
Secondary outcome measures include the impact 
of a high fibre supplement on the oral and colonic 
microbiome and biofluid metabolome.
Ethics and dissemination Approvals were obtained 
from the Alaska Area and University of Pittsburgh 
Institutional Review Boards and Alaska Native Tribal 
Health Consortium and Southcentral Foundation 
research review bodies. A data safety monitoring board, 
material transfer agreements and weekly study team 
meetings provide regular oversight throughout the 
study. Study findings will first be shared with AN tribal 
leaders, health administrators, providers and community 
members. Peer- reviewed journal articles and conference 
presentations will be forthcoming once approved by 
tribal review bodies.
Trial registration number NCT03028831.
INTRODUCTION
Diet is an environmental factor shown to 
impact colorectal cancer (CRC) risk by its 
effects on the colonic epithelium.1 Dietary 
fibre decreases CRC risk, whereas animal 
fat and red meat increase CRC risk.2 The 
human gut contains trillions of bacterial cells 
composing the gut microbiota.3 Dependent 
on food residues for survival and metabo-
lism, gut microbiota play an important role 
in human health and metabolic homeostasis 
through their production of metabolites. 
Diets high in fat stimulate bile acid produc-
tion in the liver. While the vast majority of 
bile acids are reabsorbed at the terminal 
ileum, approximately 5% are excreted into 
the colon. In the colon, primary bile acids 
are converted by gut bacteria into secondary 
bile acids that exhibit neoplastic properties. 
Conversely, fermentation of fibre by gut 
bacteria produces metabolites. Short- chain 
fatty acids (SCFA), including acetate, propio-
nate and butyrate, not only provide food for 
Strengths and limitations of this study
 ► Compliance of participants in the study has been 
excellent, due in part to the directly observed con-
sumption of the supplementation or visualisation 
using real- time video via smartphone technologies.
 ► We have a strong and dedicated study team and a 
participant population very interested in helping to 
prevent colorectal cancer (CRC).
 ► While the population has high incidence of CRC and 
many patients are scheduled for screening colonos-
copy, multiple exclusion criteria appropriate for this 
study limit the numbers eligible, especially in the 
older age range.
 ► In addition to slow and limited enrolment, the study 
was interrupted for 3 months during the COVID-19 
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the colonic epithelium but also exert regulatory effects 
on colonic mucosal inflammation and proliferation.4 5
Age- adjusted annual CRC incidence among Alaska 
Native (AN) people is the highest reported worldwide,6 
with an annual Alaska- wide rate of 89/100 000.7 This rate is 
nearly double that of African Americans (45/100 000 per 
year), who have the second highest incidence in the USA 
and stands in stark contrast to other populations, such as 
rural Africans (RAs), with less than 5/100 000 new cases 
annually.8 Remarkably, the high CRC incidence reported 
in AN people is relatively recent, as chronic diseases were 
rarely documented a mere 65 years ago.9 While cancer 
case reporting as well as healthcare and life expectancy 
have improved over this time period,9–11 the very high 
incidence of CRC signals an urgent need for research to 
identify probable causes and propose important solutions 
to reduce AN CRC rates and risks.
AN people have faced and adapted to vast cultural 
and lifestyle changes, not the least of which have been 
dramatic dietary changes.12–14 These changes have 
resulted in a transition away from traditional, nutrient- 
dense subsistence foods to commercially prepared, high- 
energy foods and beverages low in nutritional value.15–19 
Importantly, fibre, which plays a major role in establishing 
and maintaining colon health, is a key ingredient missing 
in what is described as a ‘westernised’ diet. Recent dietary 
studies conducted with AN people demonstrating a very 
low intake of approximately 13 g fibre daily15 17 19 20 led 
us to collect self- reported diet intake and analyse stool 
contents in two groups of AN people living in two regions 
of the state: urban south central Alaska and the rural 
remote Arctic Slope region.21
In that study, participants scheduled for routine 
screening colonoscopy collected morning faecal and 
urine sample for metabolite analysis, then underwent 
colonoscopy.21 Results were compared with RA subjects 
enrolled separately, demonstrating clear differences 
between the two populations. While polyps were detected 
among 50% of AN participants, none were detected in 
the RA participants. The metabolic profiles of both urine 
and faecal samples were also significantly different. Levels 
of the faecal SCFA acetate, propionate and butyrate were 
significantly lower in the AN than the RA samples, while 
levels of the faecal primary bile acids (cholic acid and 
chenodeoxycholic acid) and secondary bile acid deoxy-
cholic acid were significantly greater in AN, compared 
with RA samples.
Based on our knowledge of fibre and operating under 
the assumption that diet intake determines colon micro-
biota composition, the Alaska Native Medical Center 
(ANMC) and the University of Pittsburgh (U Pitt) 
designed the Alaska Fiber Intervention Research Study 
randomised clinical trial to demonstrate the effects of 
supplemented diet achieving at least 50 g/day of dietary 
fibre on CRC risk in AN study volunteers. We describe 
study methods to achieve our following study aims: (1) 
determine if high fibre intake can induce clinically mean-
ingful suppression of proliferative and inflammatory 
colonic biomarkers of cancer risk (primary outcome) and 
(2) investigate our hypothesis that the high risk of colon 
cancer in AN people is a consequence of insufficient fibre 
intake leading to butyrate deficiency.
METHODS AND ANALYSIS
Study design overview
Using a parallel fibre and control group design, 
randomised by minimisation,22 23 we are measuring the 
effects of a 4- week fibre (resistant starch) supplement 
compared with a 4- week placebo (digestible starch) 
supplement to participants’ normal diet on proliferative 
changes in colonic mucosal cells. We anticipate the fibre 
supplement group will demonstrate significantly reduced 
proliferative biomarkers in biopsies obtained after the 
4- week resistant starch supplement than the control 
group (primary endpoint). We will additionally measure 
and compare colonic microbiota composition, activity 
and the metabolome between groups to investigate the 
mechanisms responsible for differences in biomarkers.
The study is tied to usual care. Patients undergoing 
a routine screening colonoscopy, who are eligible and 
willing to participate, receive baseline assessments and 
specimen/data collection at the time of colonoscopy (see 
figure 1). This enrolment process is followed by an 8- week 
stabilisation period intended to re- establish normal gut 
microbiota post colonoscopy. At the end of stabilisation, 
study personnel randomise participants to either the 
fibre or placebo condition. During the next 28 days, each 
participant consumes their usual diet plus the supple-
ment (fibre or placebo). After 4 weeks of supplement, 
participants voluntarily undergo a flexible sigmoidoscopy 
(flex sig) with specimen/data collection to test outcomes.
Study setting
ANMC is the sole tertiary healthcare facility serving more 
than 170 000 AN and American Indian people living in 
Alaska; the centre of the Alaska Tribal Health System 
(ATHS) is owned and operated by AN people.24 As a 
healthcare system, AN healthcare is the ATHS’s primary 
focus, in contrast to academic and research institutions 
which focus on expanding scientific knowledge.25 As this 
study demonstrates, these foci can overlap, producing the 
opportunity to collaborate on separate, but aligned goals 
to expand scientific knowledge while simultaneously 
improving public health.
Patient and public involvement
Patients were not directly involved in protocol develop-
ment. AN providers and staff contributed to study devel-
opment on behalf of patients and tribal research review 
staff and board members evaluated, edited and approved 
the protocol and all study materials. Clinic personnel 
participated in developing procedures that would mini-
mise their time and effort on study.
Participants and recruitment
We advertise the study using multiple venues, including 
tabling at large AN public gatherings, health fairs and 
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tribal events. We have study banners in clinic waiting 
areas, flyers posted in primary care clinics, Facebook 
announcements incorporating YouTube videos and AN 
digital stories and advertisements in local newspapers. 
Certified medical assistants (CMAs) and reception staff 
assist by introducing patients to the study and introducing 
them to study staff with a ‘warm handoff’.
Due to the high incidence of CRC at a relatively young 
age among AN people, CRC screening beginning at age 
40 years is standard of care; colonoscopy is the recom-
mended screening test at ANMC. AN patients sched-
uling a screening colonoscopy through the CRC clinic 
are invited to participate in the study if they meet eligi-
bility criteria. A trained study nurse with access to CRC 
clinic schedules prescreens electronic medical records 
of patients scheduled for a preoperative (preop) visit for 
inclusion/exclusion criteria 1–3 days prior to their sched-
uled preop appointment. Specific inclusion and exclu-
sion criteria are provided in table 1.
Following prescreening, the study nurse provides the 
clinic CMA with information on potential participants. 
Checking in for their appointment, CRC clinic staff direct 
these patients to complete the clinical paperwork, asking 
them to also review the study flyer. Clinic staff then direct 
interested patients to study staff.
Enrolment phase
We opened enrolment on 27 November 2017, with the 
goal to enrol 60 participants (30 participants in each study 
arm) who will complete the study. We determined statis-
tical power based on mucosal proliferation (measured 
by Ki-67 protein), the primary endpoint, using changes 
observed in a 2- week fibre supplementation study with 
African Americans.26 While a 20% difference between 
fibre and placebo implies clinical significance, we have at 
least 80% power to detect a reduction of at least 8% in the 
fibre arm from the placebo arm, using a two- sided hypoth-
esis test at α=0.05. We will also have more than adequate 
power for secondary endpoints described in table 1.26 We 
anticipate enrolling up to 100 participants to achieve 60 
study completions, with attrition due to postcolonoscopy 
ineligibility, participant scheduling conflicts, losses to 
follow- up and supplement intolerance. The enrolment 
phase consists of baseline data and procedures collected 
the day before, day of, during and after colonoscopy 
before randomisation (see figure 1).
Day before colonoscopy
Participants are usually prepped for colonoscopy the 
evening before colonoscopy. A study team member 
observes intake of the polyethylene glycol (PEG) solution 
that is free of sulfates, which are harmful to colon micro-
biota. No pre- prep instructions are required. Prior to 
prep ingestion, study personnel obtain participant height 
(via study stadiometer) and weight (via study scale) then 
calculate baseline body mass index (BMI) per the standard 
formula (weight in kilograms divided by height in metres, 
squared). Study personnel assess colonic fermentation 
Figure 1 Study design and timeline. *Twenty- four hour diet recall interviews are generally completed after the baseline 
colonoscopy and prior to randomisation and supplementation.
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measuring hydrogen (H2) and methane (CH4) produc-
tion via a breath sample, which they analyse on collection 
using a commercial analyzer (Quintron BreathTracker 
SC). Participants are also asked to provide a urine sample, 
from which 33 mL is aliquotted and stored in −80°C for 
later analysis of microbial metabolites. Participants then 
consume 2.0–2.5 L of the sulfate- free PEG solution in 
30–60 min.
During the next few hours, study personnel collect and 
aliquot the first solid stool passed (which will be analysed 
for faecal microbes and metabolites), placing it in −80°C 
and collect remaining participant evacuate for the next 
3 hours. Once the 3- hour evacuate is collected (which 
will be analysed for total colonic microbiota and their 
metabolites), study staff weigh, homogenise, aliquot and 
freeze specimens at −80°C; the 3- hour evacuate collec-
tion period provides sufficient time to obtain a food 
frequency questionnaire (FFQ) developed and validated 
for use with AN study participants27 and a baseline bowel 
function assessment. The FFQ is intended to provide a 
list of foods and approximate proportions consumed 
within the past year. In addition to commercial foods, the 
FFQ contains common AN subsistence foods, including 
Alaska fish and seafood, wild game and birds, bird eggs 
and tundra berries and greens traditionally prepared and 
preserved. The standardised bowel function assessment28 
(assessing usual bowel habits, frequency, consistency) has 
been employed in prior U Pitt studies.8 26 On completion 
of the prep and precolonoscopy procedures, participants 
have nothing more by mouth and report to the surgery 
suite at their designated time with an escort.
Day of colonoscopy prior to procedure
The ANMC surgeon/endoscopist performs colonoscopy 
under conscious sedation per standard clinical proce-
dure. Clinical staff placing the intravenous line draw off 
30 cc of blood for study purposes prior to starting the 
fluid drip. Study staff transfer blood collected for the 
study to the appropriate tubes for ANMC lab analyses and 
future U Pitt analyses. Baseline study analyses performed 
at the ANMC lab include: fasting blood count, complete 
metabolic profile, lipoproteins, triglycerides, folate and 
vitamins B-12 and D to assess nutritional status. Study staff 
additionally prepare and aliquot whole blood and serum 
samples, which are placed in −80°C until shipped to U 
Pitt for additional analyses (see table 1).
Intraoperative
In addition to any clinical biopsies necessary, study biop-
sies are taken from normal- appearing mucosa at the 
cecum, mid- traverse and sigmoid colon (25 cm from the 
anal verge). Study biopsy material will be used to measure 
colon cancer biomarkers and mucosa- attached microbes. 
One biopsy at each region is flash frozen in liquid 
nitrogen and placed in a −80°C freezer. A second biopsy 
from each region is placed in RNAlater solution, flash 
frozen in liquid nitrogen, refrigerated overnight and the 
RNAlater solution pipetted off the next day before being 
frozen at −80°C. A third biopsy at each region is preserved 
in formalin and stored at room temperature.
Post colonoscopy prior to randomisation
The study nurse reviews the participant’s colonoscopy 
results to determine continued study eligibility. If colo-
noscopy findings do not include any items listed in the 
exclusion criteria, participants remain eligible for study 
participation. At this point, participants enter the stabi-
lisation phase. This phase overlaps with the enrolment 
phase until study staff collect all enrolment materials, 
which include two 24- hour diet recalls, 1 week day and 
1 weekend day, using the Nutrition Data System for 
Research (NDSR, Nutrition Coordinating Center, Univer-
sity of Minnesota, Minneapolis, Minnesota; versions 2017 
through 2020).29 Study staff conducting 24- hour recalls 
are trained in NDSR procedures, having completed 10 
practice collections and a final mock collection interview 
with a NDSR- prepared study staff member. On enrolment 
phase completion, we provide participants a $100 enrol-
ment gift card in appreciation for their time and effort.
Stabilisation phase
During the stabilisation phase, participants resume their 
usual diet. An 8- week stabilisation period is intended 
to re- establish resident microbiota eliminated with the 
Table 1 Inclusion/exclusion criteria for the Alaska FIRST 
clinical trial
Category Description




Living within the south central (Anchorage, 
Alaska) area
Scheduled at ANMC for a routine colonoscopy
Exclusion Family history of familial adenomatous 
polyposis, Lynch syndrome or hereditary non- 
polyposis CRC
Previously diagnosed with inflammatory bowel 
disease or colon cancer
Personal history of kidney or liver disease or 
bleeding disorder
Previous gastrointestinal surgery resulting in 
disturbed gut function due to loss of bowel or 
altered anatomy
Any form of chronic gastrointestinal disease 
resulting in disturbed gut function, diarrhoea or 
malabsorption were excluded from the study
Antibiotic treatment within the past 12 weeks
Current and regular treatment with steroids
Prescribed diabetes medication
ANMC, Alaska Native Medical Center; BMI, body mass index; 
CRC, colorectal cancer; FIRST, Fiber Intervention Research Study.
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colonoscopy prep.26 30 31 During this period, study activities 
are limited to participant randomisation and establishing 
a supplementation phase start date, both occurring at the 
end of the stabilisation phase.
We use minimisation as the method of randomisa-
tion. Minimisation is better than simple randomisation 
for balancing prognostic factors that could bias study 
outcomes between arms.22 23 In this study, minimisation 
assigns participants to fibre versus control groups to 
maintain the balance of the following factors, listed in 
order of priority: prior polypectomy, sex, BMI (<30 kg/m2 
versus ≥30 kg/m2) and fish consumption (<4 servings per 
week versus ≥4 servings). Minimisation is implemented 
via an R script with an e- mail front end written in Python 
2.6 running at U Pitt.
On assignment, Alaska Native Tribal Health Consortium 
(ANTHC) Study staff are provided a randomly numbered 
code to assign to each new participant. These codes 
match coded labels on the supplement packets previ-
ously mailed to the ANTHC Study team and are the only 
information provided on the packets. Only designated 
U Pitt Study team members have access to the identity 
of the supplement and only ANTHC Study staff can link 
Study IDs to participant identifiers, so the double blind 
and participant confidentiality are maintained. Should 
the need arise to identify which product an individual is 
assigned (eg, complaints of supplement intolerance), a 
two- person process is in place.
Supplementation phase
The supplementation phase begins with supplement 
initiation. Study personnel contact participants to set up 
their direct observed supplement intake for 28 consec-
utive days. Study staff work closely with participants to 
time the supplement so that the date of follow- up flex sig 
performed on the 29th day is convenient for the partic-
ipant, available and scheduled in advance. Prior to initi-
ating supplementation, study staff collect presupplement 
weight as well as stool and saliva samples. Both samples 
are stored frozen at −80°C until shipped to U Pitt for anal-
ysis. We plan to analyse saliva samples collected using an 
OMNIgene oral kit (DNA Genotek, Inc.) to compare oral 
and colon microbiomes pre and post supplementation.
Study supplement packets for both fibre and placebo 
groups are prepared by Ingredion (Bridgewater, New 
Jersey) and shipped to U Pitt. For the fibre group, supple-
ment is given as a daily dose of 70 g high- amylose maize 
starch, containing 42 g of resistant starch. Supplements 
are analysed by the Englyst method to confirm the precise 
amount of resistant starch given.32 Data from previous AN 
studies suggest that the usual AN diet contains approxi-
mately 13 g of fibre per day.15 17 19 Thus, total fibre intake 
would be about 55 g per day, a quantity sufficient to 
suppress colon cancer biomarkers (see table 2 measured 
outcomes) after 2 weeks in previous studies.26 33 34
While participants in the placebo group also continue 
their usual diet, supplement packets for this group (also 
prepared by Ingredion) contain 35 g of fully digestible 
starch (ie, corn starch), weighed, analysed, prepared and 
presented in the same way. Fibre and placebo supple-
ments are equal in calories, packaged identically in daily 
dose packets and appear and taste similar, thus main-
taining the double blind. Due to the substantial increase 
of fibre from 13 to 55 g/day, previous tolerance tests 
with AN volunteers prior to this study were performed 
and demonstrated the supplement was well tolerated as a 
single or divided dose mixed into 300 mL water taken for 
a period of a week.
Ingredion sends complete batches of single- dose packets 
of each supplement type to U Pitt, where U Pitt Study staff 
apply assignment code labels corresponding to the codes 
generated by the electronic minimisation programme, 
plus a daily sequence number (day 1–day 35). Batches of 
35 labelled packets are shipped in advance to the ANTHC 
Study team. Once participants are randomised and 
assigned a supplement code, ANTHC Study staff locate 
the packet batch. An additional week of packets are avail-
able should a flex sig procedure be unexpectedly delayed.
Each participant is provided a shaker bottle and 
instructions (with in- person demonstration, as needed) 
for mixing the supplement packet with 300 mL water (or 
other preferred liquid). Study staff work closely with each 
participant to plan 28 consecutive days where each partic-
ipant is directly observed mixing and drinking the supple-
ment, which can be done in- person or via FaceTime or 
Google Duo and includes weekends and holidays. The 
first supplement is done in the presence of study staff 
for quality assurance, reserving a 5 mg sample to validate 
content and requesting participants assume usual diet 
and take the supplement about the same time each day.
Study staff also provide instruction on completing a 
daily food log and daily bowel function form and provide 
collection supplies for the first stool the next week. At the 
completion of each week, study staff collect all completed 
daily food logs, bowel function forms and an end- of- week 
stool sample. Participants are reweighed and given their 
weekly stool sample collection kit and the next week’s 
supply of supplement. Participant weight and supplement 
tolerance are thus monitored throughout the supple-
mentation period. Any participant with a 2 kg change in 
weight or gastrointestinal complaints during the supple-
mentation phase is referred to the study dietician for eval-
uation. On completion of all weekly supplement intake, 
assessment forms, weight and sample collections, each 
participant receives a $75 gift card.
On entering the fourth week of supplementation, study 
staff prepare for the study flex sig procedure. Measure-
ments (except height) and specimens collected pre colo-
noscopy are repeated. Participants revisit the CRC clinic 
preoperatively and prior to starting the sulfate- free PEG 
prep solution, study staff collect a saliva sample. The rest 
of the flex sig prep is conducted similarly to the baseline 
colonoscopy.
Previous studies show changes in the sigmoid mucosa 
reflect changes in the proximal colon.26 35 A flex sig is 
thus sufficient for postsupplementation biopsies. Three 
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biopsies from normal appearing mucosa in two regions 
of the colon, the sigmoid (25 cm from the anal verge) 
and the splenic flexure (or the furthest region easily 
accessed), are obtained by an ANMC surgeon/endosco-
pist. On procedure completion, participants receive a 
$300 gift card in appreciation for their participation.
Data entry/specimen storage and transfer to U Pitt
The large number of procedures performed and spec-
imens/data collected throughout this trial require 
detailed documentation, accurate labelling and strict 
attention to protocol. Working with ANMC providers and 
staff in clinics, preop and endoscopy suites and labora-
tory and pathology departments, ANMC and U Pitt Study 
teams created more than 90 standard operating proce-
dures and clinical report forms (CRFs) contained in the 
study manual of operations. Because procedure data and 
biospecimen collection do not all occur in a set location 
with reliable access to Wi- Fi or the internet, much of the 
documentation is initially charted on paper forms and 
maintained in participant folders. All data and specimens 
collected are associated with only an anonymous study 
identification number and accessible only to the ANTHC 
Study team.
Study team members enter all CRF data into Research 
Electronic Data Capture (REDCap) databases housed 
within protected servers at ANTHC and U Pitt, each 
containing different data elements. REDCap is a 
secure, web- based, data capture application designed 
for research studies.36 The U Pitt database, made acces-
sible to the ANTHC Study team, houses data relevant to 
biospecimens (blood, urine, stool and saliva aliquots and 
biopsy samples), which study staff batch and ship to U 
Pitt for analysis throughout the study. All but the formalin 
preserved tissue samples are frozen at −80°C and housed 
first in ANTHC Study freezers then shipped overnight on 
dry ice by FedEx to U Pitt. A second REDCap database 
created by the ANTHC Study team captures CRF informa-
tion, including laboratory and anthropometry data, daily 
food intake and bowel function information and breath 
and saliva sample collection data. A third database (also 
housed at ANTHC), directly captures FFQ data collected 
during the baseline colonoscopy prep period. Institu-
tional database administrators set individual data access 
to specific data and the level of access (eg, data entry, 
data download, view only), including access for external 
collaborators.
Proposed analyses
Study analyses are designed to test the hypothesis that 
the risk of CRC in AN people is primarily a consequence 
of fibre intake less than the recommended 30 g/day. 
The primary outcome measured in our study is colonic 
epithelial proliferation rate measured by Ki67 staining of 
proliferative cells to determine whether a high fibre diet 
can induce clinically meaningful (ie, >20% the difference 
distinguishing high from low risk populations, termed 
‘responders’) suppression of this proliferative cancer risk 
biomarker.8 37 In addition, secondary outcomes include 
inflammatory markers of the gut mucosa and the impact 
of a high fibre diet on expression of host genes respon-
sive to diet and microbial metabolites, clinical blood labs, 
faecal and oral microbiome and faecal, blood and urine 
metabolome. We will explore the impact of the gut and 
oral microbiome and faecal, urine and blood metabolome 
on host biomarkers and host- microbe cometabolism. We 
will assess postsupplement changes in markers by gener-
alised linear models. The nature of the data will deter-
mine whether these models are linear, logistic, Poisson 
or require further transformation. Table 2 contains more 
detailed information regarding the measured endpoints.
ETHICS AND DISSEMINATION
This ongoing 5- year study is funded by the National Insti-
tutes of Health through a National Cancer Institute grant 
(CA204403) awarded to the U Pitt with a subaward to the 
ANTHC.
Permissions and approvals
The U Pitt and Alaska Area institutional review boards 
(IRBs) reviewed and approved this study. Boards of direc-
tors for ANTHC and Southcentral Foundation (SCF) 
provided tribal review and approval. ANTHC and SCF are 
tribal health organisations (THOs) operating the ANMC 
located in Anchorage, Alaska. While IRBs focus on the 
protection of human participants in research, THOs 
focus attention on protecting AN communities and 
culture. Tribal approval is required for all health research 
proposals with AN people.
Study oversight
All clinical trials supported by the National Cancer Insti-
tute (NCI) require monitoring. Monitoring should reflect 
the degree of risk involved in participation of the clin-
ical trial. We established a data safety monitoring board 
(DSMB), fully executed institutional material transfer 
agreements with all collaborators and created an internal 
investigator team, providing these additional layers of 
study oversight distinct from the IRB and tribal review 
process.
The DSMB is comprised of three external experts in 
nutrition and gastrointestinal research, the study prin-
cipal investigator, the ANTHC project director and the 
NCI programme officer. Meeting annually, the DSMB 
reviews an annual report of research activities and 
addresses analyses performed, preliminary outcome 
data, adverse side effects or toxicity caused by treatments, 
inclusion and exclusion criteria, enrolment procedures 
and modifications to any elements of the study.
Signed material transfer agreements between all collab-
orating institution clearly state the terms under which 
tribal data and specimens will be shared, maintained 
and destroyed and results reported. U Pitt and ANTHC 
investigators and study staff meet weekly (virtually or by 
teleconference) to discuss study progress and address 
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challenges. Additional attendees are present on request 
(eg, U Pitt biostatistician, data managers).
Results dissemination
Tribal review of research findings is the first step in results 
dissemination, per ANTHC research policy. We will 
provide early reports and presentations of the findings to 
ANTHC and SCF Board members, health administrators 
and healthcare providers. As these study findings most 
directly affect AN people, dissemination plans include 
mass media announcements and messaging through 
ANTHC’s Marketing Department. Because this study will 
demonstrate important findings relevant to other popu-
lations having transitioned to a westernised diet, we will 
inform the scientific community through professional 
presentations and peer- reviewed journal articles that have 
received tribal review and approval prior to submission.
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